What Is KPV? The Alpha-MSH Tripeptide — Structure, Mechanism and Research Profile

KPV — lysine-proline-valine — reproduces the final three C-terminal residues of alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers use it as a minimal anti-inflammatory motif that seems to keep the parent hormone's immunomodulatory profile while losing its pigment-related signalling. With a molecular weight of just 342.43 g/mol it ranks among the smallest compounds in any research-peptide range, and that small size governs how it behaves in the lab: many micromoles per milligram, effortless solubility in water, and a published record built mostly on cell culture and rodent models of gut and skin inflammation.

Here we explain what KPV is, the origin of its sequence, the mechanisms proposed for it, the research fields that use it, and the practicalities — vial sizes, concentration arithmetic, storage and how to read the certificate.

Where KPV comes from: the C-terminal tripeptide of alpha-MSH

Alpha-MSH is a 13-amino-acid peptide cleaved from proopiomelanocortin and is best known for driving pigmentation via the melanocortin receptors. Beginning in the 1990s, research on the hormone pulled apart two activities that had earlier been lumped together: receptor-driven pigment signalling, which depends mainly on the central His-Phe-Arg-Trp motif, and anti-inflammatory activity, which several laboratories traced to the C-terminal end.

KPV is that C-terminal end. Lacking the core "message" sequence needed for high-affinity binding at MC1R and MC4R, it is usually described as working largely outside classical melanocortin receptor signalling — precisely what made it a useful research tool rather than an oddity. As a tripeptide it is very inexpensive to produce by solid-phase synthesis, chemically robust and freely soluble in water, and it has none of the disulfide bonds, oxidation-sensitive methionines or deamidation-prone asparagines that make longer peptides awkward.

One structural point is critical for molar calculations. At 342.43 g/mol, KPV weighs about a quarter as much as BPC-157 by mass and roughly one-thirteenth as much as LL-37. A 5 mg vial therefore holds about 14.6 micromoles — much more material on a molar basis than 5 mg of almost any other product in the range. Comparisons made per milligram rather than per mole will consistently misjudge KPV.

Proposed mechanisms of action

The most consistently reported effect is disruption of NF-kappa B signalling. Cell culture studies describe KPV reducing the movement of NF-kappa B subunits into the nucleus and decreasing transcription of pro-inflammatory mediators downstream, among them IL-6, IL-8 and TNF-alpha. This is an intracellular effect rather than a receptor-binding event, which immediately prompts the question of how a water-loving tripeptide gets into the cytoplasm.

Intestinal researchers point to the peptide transporter PepT1. Several groups report that colonic epithelial cells take up KPV via this di-/tripeptide carrier, which is barely expressed in healthy colon but increases in inflamed tissue. If correct, this yields a neat selectivity argument: uptake would be highest precisely where the transporter is most abundant. It should nonetheless be regarded as a reported mechanism, not an established one — transporter-dependent uptake has been demonstrated in particular cell lines and models, and how far it generalises remains open.

A third line of work involves direct antimicrobial and antifungal effects. At high concentrations in vitro, alpha-MSH and its C-terminal fragments have been reported to reduce the viability of some bacteria and yeasts — an activity mechanistically unrelated to the NF-kappa B findings and supported by a much smaller literature.

Research applications

Intestinal inflammation models (rodent and in vitro)

Most published KPV research concerns experimental colitis. In chemically induced rodent colitis, animals receiving the peptide have shown lower histological damage scores, reduced myeloperoxidase activity and decreased pro-inflammatory cytokine expression, and several papers concentrate on delivering it to the colon orally or via nanoparticles rather than systemically. Complementary in-vitro studies use intestinal epithelial monolayers to measure barrier integrity and cytokine release. All of this is preclinical; there are no human trial data supporting KPV for any indication.

Epithelial barrier function and mucosal repair

Since barrier integrity and inflammation are linked, KPV also features in studies measuring tight-junction protein expression and transepithelial electrical resistance in monolayers. Researchers comparing barrier mechanisms often place it next to larazotide acetate, which acts directly on the zonulin pathway rather than via cytokines — an informative contrast, as the two intervene at different points in the same physiology.

Skin and wound-healing models

A smaller body of work looks at KPV in skin inflammation and wound-repair models, echoing the dermatological roots of alpha-MSH research. In this setting it is often studied together with GHK-Cu, which is investigated for matrix remodelling rather than cytokine suppression.

Blends and combination studies

KPV is an ingredient in several multi-peptide research preparations, such as the KLOW blend and BPC-157 + KPV. Published work has not settled whether such combinations do anything beyond the sum of their parts; our guide comparing blends with single vials discusses the interpretation problems that arise when a certificate describes a mixture.

Available formats and vial sizes

KPV is available as lyophilized injectable-format vials of 5 mg (€50) and 10 mg (€75). Thanks to its low molecular weight, these quantities support many plate-based experiments; labs making molar-matched comparisons with bigger peptides typically find a 5 mg KPV vial lasts longer than a 10 mg vial of a 3 kDa peptide.

For studies needing a gastrointestinal presentation there are two oral formats: KPV capsules and BPC-157 + KPV capsules. All related products are listed under anti-inflammatory peptides, with the gut-focused selection under gut health peptides.

Reconstitution and storage at the bench

Reconstitution here is purely a calculation, not an administration protocol. Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL (5,000 mcg/mL), so withdrawing 0.1 mL — 10 units on a U-100 syringe scale — removes 500 mcg. In molar terms, 5 mg/mL of a 342.43 g/mol peptide is roughly 14.6 mM, a number worth working out before preparing culture dilutions, since the working concentrations reported in cell studies are usually micromolar and call for considerable serial dilution.

KPV dissolves readily in water and needs neither pH adjustment nor the organic co-solvents some hydrophobic peptides require. Keep lyophilized vials at −20 °C away from light and moisture; refrigerate reconstituted solution and split it into aliquots so that no single tube is warmed and cooled repeatedly. Our peptide storage guide and reconstitution guide cover handling in full, and the reconstitution calculator can be used to check the maths.

Purity and reading the certificate of analysis

Each lot is purified by reversed-phase HPLC to 99% or better and confirmed by mass spectrometry, with a certificate tied to the lot number on the vial. For a tripeptide, three checks carry the most weight. First, make sure the measured mass agrees with 342.43 g/mol for the free peptide — short sequences are the simplest of all to confirm by mass, so an unclear spectrum is unacceptable. Second, examine the HPLC trace itself, not just the purity figure: a properly purified tripeptide should give one sharp peak on a flat baseline. Third, look at the counter-ion. Small peptides are often delivered as TFA salts, and residual trifluoroacetate has documented effects in cell culture; once salt and residual water are taken into account, net peptide content is lower than the gross weight in the vial. Our COA reading guide and HPLC purity explainer walk through real chromatograms.

Regulatory position

KPV is not an approved medicine in the United States, the EU or anywhere else, and holds no marketing authorisation for any use. It is not a food supplement ingredient, nor a generally available compounded medicine. The line between research-grade material and an authorised product is more than a technicality: it defines which claims may be made and what documentation exists. KPV is supplied for laboratory research only, not for human consumption.

Related compounds and further reading

Elsewhere in the anti-inflammatory group, ARA-290 targets inflammation through the innate repair receptor and VIP through VPAC receptor signalling — three distinct routes into overlapping biology. For a head-to-head structural and mechanistic comparison, read BPC-157 vs KPV. Wider context is available in the gut health research overview and the healing and recovery overview, and the institutional catalogue lists related products on the melanocortin family and MSH family pages.